De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

导出 OA

翻译打印收藏纠错

作者： Antonio R,Lucena-Araujo ^[1] ; Jason P,Moran ^[1] ; Paul A,VanderLaan ^[2] ; Dora,Dias-Santagata ^[3] ; Erik,Folch ^[4] ; Adnan,Majid ^[4] ; Michael S,Kent ^[5] ; Sidharta P,Gangadharan ^[5] ; Deepa,Rangachari ^[1] ; Mark S,Huberman ^[1] ; Susumu S,Kobayashi ^[6] ; Daniel B,Costa ^[7]

作者单位： Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ^[1] Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ^[2] Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ^[3] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ^[4] Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ^[5] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: skobayas@bidmc.harvard.edu. ^[6] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dbcosta@bidmc.harvard.edu. ^[7]

关键词 ALK Adenocarcinoma Crizotinib Kinase domain Lung cancer Mutation